Knight Cancer Institute

Research Output 1990 2019

Filter
Short survey
2018
18 Citations (Scopus)

Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

Prasad, V., Kaestner, V. & Mailankody, S., Feb 1 2018, In : JAMA oncology. 4, 2, p. 157-158 2 p.

Research output: Contribution to journalShort survey

DNA Mismatch Repair
Tumor Biomarkers
Pharmaceutical Preparations
Neoplasms
pembrolizumab

Making room

Lycette, J., Jun 26 2018, In : JAMA - Journal of the American Medical Association. 319, 24, p. 2479-2480 2 p.

Research output: Contribution to journalShort survey

2017
10 Citations (Scopus)

Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world

Mailankody, S. & Prasad, V., Jul 1 2017, In : JAMA oncology. 3, 7, p. 889-890 2 p.

Research output: Contribution to journalShort survey

Biomarkers
Pharmaceutical Preparations
Neoplasms
5 Citations (Scopus)

Pharmaceutical marketing for rare diseases: Regulating drug company promotion in an era of unprecedented advertisement

Mailankody, S. & Prasad, V., Jun 27 2017, In : JAMA - Journal of the American Medical Association. 317, 24, p. 2479-2480 2 p.

Research output: Contribution to journalShort survey

Medicine in Art
Patient Acceptance of Health Care
Pyrazoles
Janus Kinase 2
Drug Prescriptions

The puzzle table

Lycette, J., Dec 1 2017, In : Journal of Clinical Oncology. 35, 34, p. 3888-3889 2 p.

Research output: Contribution to journalShort survey

2016
14 Citations (Scopus)

Blood-based screening for colon cancer: A disruptive innovation or simply a disruption?

Parikh, R. B. & Prasad, V., Jun 21 2016, In : JAMA - Journal of the American Medical Association. 315, 23, p. 2519-2520 2 p.

Research output: Contribution to journalShort survey

Septins
Precancerous Conditions
Predictive Value of Tests
Colonoscopy
Feces
3 Citations (Scopus)

Duration of adjuvant therapy for patients with gastrointestinal stromal tumors: Where is goldilocks when we need her?

Blanke, C. & DeMatteo, R. P., Jun 1 2016, In : JAMA oncology. 2, 6, p. 721-722 2 p.

Research output: Contribution to journalShort survey

Medication Therapy Management
Molecular Targeted Therapy
Gastrointestinal Stromal Tumors
Therapeutics
Imatinib Mesylate
16 Citations (Scopus)

Implications of proposed medicare reforms to counteract high cancer drug prices

Mailankody, S. & Prasad, V., Jul 19 2016, In : JAMA - Journal of the American Medical Association. 316, 3, p. 271-272 2 p.

Research output: Contribution to journalShort survey

Financial Risk Sharing
Medicare Part B
Cost Sharing
Physicians' Practice Patterns
Incentive Reimbursement
1 Citation (Scopus)

Neglected - Cancer care and mental health in rural America

Lycette, J., Dec 8 2016, In : New England Journal of Medicine. 375, 23, p. 2220-2221 2 p.

Research output: Contribution to journalShort survey

Rural Health Services
Neglected Diseases
Bipolar Disorder
Mental Health
Breast Neoplasms
9 Citations (Scopus)

The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable

Prasad, V. & Mailankody, S., Jun 1 2016, In : Mayo Clinic Proceedings. 91, 6, p. 707-712 6 p.

Research output: Contribution to journalShort survey

Drug Costs
Pharmaceutical Preparations
Neoplasms
2015
7 Citations (Scopus)

Losing "losing the battle with cancer"

Ellis, L. M., Blanke, C. & Roach, N., Apr 1 2015, In : JAMA oncology. 1, 1, p. 13-14 2 p.

Research output: Contribution to journalShort survey

Attitude to Death
Treatment Refusal
Attitude of Health Personnel
Medical Futility
Unnecessary Procedures